Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse af Guselkumab hos pædiatriske deltagere med moderat til svært aktiv Crohns sygdom (MACARONI-23)

2. november 2026 opdateret af: Janssen Research & Development, LLC

En fase 3, multicenter, randomiseret, platformsundersøgelse af p19-hæmning af IL-23-vejen til at etablere effektivitet ved pædiatrisk Crohns sygdom

The purpose of this study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical response to guselkumab at Week 12.

Studieoversigt

Status

Rekruttering

Betingelser

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

120

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • Nedlands, Australien, 6009
        • Rekruttering
        • Perth Children's Hospital
      • South Brisbane, Australien, 4101
        • Rekruttering
        • Mater Hospital Brisbane
      • Westmead, Australien, 2145
        • Rekruttering
        • The Children's Hospital at Westmead
      • Brussels, Belgien, 1090
        • Rekruttering
        • Universitair Ziekenhuis Brussel
      • Brussels, Belgien, 1200
        • Rekruttering
        • Cliniques Universitaires Saint Luc
      • Ghent, Belgien, 9000
        • Rekruttering
        • Universitair Ziekenhuis Gent
      • Leuven, Belgien, 3000
        • Rekruttering
        • UZ Leuven
      • Campinas, Brasilien, 13060-904
        • Rekruttering
        • Sociedade Campineira de Educacao e Instrucao Hospital e Maternidade Celso Pierro
      • Curitiba, Brasilien, 80250-060
        • Rekruttering
        • Associacao Hospitalar de Protecao a Infancia Dr. Raul Carneiro
      • Goiânia, Brasilien, 74605-020
        • Rekruttering
        • Universidade Federal de Goias - Hospital das Clinicas da UFG
      • Porto Alegre, Brasilien, 90035-074
        • Rekruttering
        • Irmandade Santa Casa de Misericordia de Porto Alegre
      • Porto Alegre, Brasilien, 90035-007
        • Rekruttering
        • Hospital De Clinicas De Porto Alegre
      • Vitória, Brasilien, 29040-091
        • Rekruttering
        • Centro de Ciencias e Saude da Universidade Federal do Espirito Santo-Nucleo de Doencas Infecciosas
      • Votuporanga, Brasilien, 100000
        • Rekruttering
        • INTEGRAL Pesquisa e Ensino
    • Nova Scotia
      • Halifax, Nova Scotia, Canada, B3K 6R8
        • Rekruttering
        • Iwk Health Centre
    • Ontario
      • London, Ontario, Canada, N6A 5W9
        • Rekruttering
        • London Health Sciences Centre Victoria Hospital
      • Toronto, Ontario, Canada, M5G 1X8
        • Rekruttering
        • Hospital For Sick Children
      • Glasgow, Det Forenede Kongerige, G51 4TF
        • Rekruttering
        • Royal Hospital for Sick Children
      • London, Det Forenede Kongerige, WC1N 3JH
        • Rekruttering
        • Great Ormond Street Hospital
      • Manchester, Det Forenede Kongerige, M13 9WL
        • Rekruttering
        • Royal Manchester Children's Hospital
      • Manchester, Det Forenede Kongerige, M13 9WL
        • Rekruttering
        • Nowgen Centre, Research and Innovation
      • Oxford, Det Forenede Kongerige, OX3 9DU
        • Rekruttering
        • John Radcliffe Hospital
      • Sheffield, Det Forenede Kongerige, S10 2TH
        • Rekruttering
        • Sheffield Children's Hospital
    • California
      • Los Angeles, California, Forenede Stater, 90048
        • Rekruttering
        • Cedars Sinai Medical Center
    • Connecticut
      • Hartford, Connecticut, Forenede Stater, 06106
        • Rekruttering
        • Connecticut Children's Medical Center
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30322
        • Rekruttering
        • Emory University
      • Atlanta, Georgia, Forenede Stater, 30342
        • Rekruttering
        • Children's Center for Digestive Health Care
    • Indiana
      • Indianapolis, Indiana, Forenede Stater, 46202-5225
        • Rekruttering
        • Riley Hospital for Children
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02115
        • Rekruttering
        • Boston Childrens Hospital
    • New Jersey
      • Morristown, New Jersey, Forenede Stater, 07960
        • Rekruttering
        • Goryeb Children's Hospital
    • New York
      • New York, New York, Forenede Stater, 10029
        • Rekruttering
        • Icahn School of Medicine at Mount Sinai
      • New York, New York, Forenede Stater, 10032
        • Rekruttering
        • Columbia University Medical Center
      • New York, New York, Forenede Stater, 10021-5663
        • Rekruttering
        • Weill Cornell Medical College - Judith Jaffe Multiple Sclerosis Center
    • Ohio
      • Dayton, Ohio, Forenede Stater, 45404
        • Rekruttering
        • The Children's Medical Center of Dayton
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19104
        • Rekruttering
        • Children's Hospital of Philadelphia
    • Texas
      • Fort Worth, Texas, Forenede Stater, 76104
        • Rekruttering
        • Cook Childrens Medical Center
    • Vermont
      • Colchester, Vermont, Forenede Stater, 05446
        • Rekruttering
        • University of Vermont Medical Center
      • Amiens, Frankrig, 80054
        • Rekruttering
        • CHU Amiens-Hopital Nord
      • Lille, Frankrig, 59037
        • Rekruttering
        • Hôpital Jeanne de FLANDRE, CHRU LILLE
      • Paris, Frankrig, 75019
        • Rekruttering
        • Hôpital Robert Debré
      • Paris, Frankrig, 75015
        • Rekruttering
        • Hôpital Necker - Enfants Malades
      • Rotterdam, Holland, 3015 GD
        • Rekruttering
        • Erasmus Medisch Centrum
      • Beersheba, Israel, 84101
        • Rekruttering
        • Soroka University Medical Center
      • Be’er Ya‘aqov, Israel, 70300
        • Rekruttering
        • Shamir Medical Center Assaf Harofeh
      • Jerusalem, Israel, 9103102
        • Rekruttering
        • Shaare Zedek Medical Center
      • Jerusalem, Israel, 9124001
        • Rekruttering
        • Hadassah Medical Center
      • Petah Tikva, Israel, 4920235
        • Rekruttering
        • Schneider Children's Medical Center
      • Rehovot, Israel, 761001
        • Rekruttering
        • Kaplan Medical Center
      • Alessandria, Italien, 15121
        • Rekruttering
        • A.O. Santi Antonio e Biagio e Cesare Arrigo
      • Bergamo, Italien, 24127
        • Rekruttering
        • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
      • Bologna, Italien, 40124
        • Rekruttering
        • Ospedale Bellaria, U.O.Cardiologia Az. USL di Bologna
      • Florence, Italien, 50139
        • Rekruttering
        • Azienda Ospedaliero Universitaria Ospedale Pediatrico Meyer
      • Milan, Italien, 20154
        • Rekruttering
        • Azienda Socio Sanitaria Territoriale Fatebenefratelli Presidio Ospedale dei Bambini Vittore Buzzi
      • Roma, Italien, 161
        • Rekruttering
        • AOU Policlinico Umberto I
      • Hirosaki, Japan, 036-8563
        • Rekruttering
        • Hirosaki University Hospital
      • Kagoshima, Japan, 890-8544
        • Rekruttering
        • Kagoshima University Hospital
      • Kashiwa-shi, Japan, 277-0871
        • Rekruttering
        • Tsujinaka Hospital Kashiwanoha
      • Kobe, Japan, 650 0017
        • Rekruttering
        • Kobe University Hospital
      • Saga, Japan, 849-8501
        • Rekruttering
        • Saga University Hospital
      • Sendai, Japan, 989-3126
        • Rekruttering
        • Miyagi Childrens Hospital
      • Setagaya Ku, Japan, 157 8535
        • Rekruttering
        • National Center for Child Health and Development
      • Tokyo, Japan, 113-8431
        • Rekruttering
        • Juntendo University Hospital
      • Tsu, Japan, 514 8507
        • Rekruttering
        • Mie University Hospital
      • Ube, Japan, 755-8505
        • Rekruttering
        • Yamaguchi University Hospital
      • Yokohama, Japan, 232-0024
        • Rekruttering
        • Yokohama City University Medical Center
      • Yokohama, Japan, 230-8765
        • Rekruttering
        • Saiseikai Yokohamashi Tobu Hospital
      • Nordbyhagen, Norge, 1474
        • Rekruttering
        • Akershus Universitetssykehus HF
      • Oslo, Norge, 424
        • Rekruttering
        • Oslo University Hospital
      • Tromsø, Norge, 9038
        • Rekruttering
        • Universitetssykehuset Nord-Norge HF
      • Trondheim, Norge, 7030
        • Rekruttering
        • St. Olavs Hospital
      • Rzeszów, Polen, 35-302
        • Rekruttering
        • Korczowski Bartosz Gabinet Lekarski
      • Warsaw, Polen, 04 501
        • Rekruttering
        • WIP Warsaw IBD Point Profesor Kierkus
      • Warsaw, Polen, 04 730
        • Rekruttering
        • Instytut Pomnik Centrum Zdrowia
      • Braga, Portugal, 4710-243
        • Rekruttering
        • Hospital de Braga
      • Lisbon, Portugal, 1649-035
        • Rekruttering
        • Centro Hospitalar de Lisboa Norte Hospital Santa Maria
      • Porto, Portugal, 4200-319
        • Rekruttering
        • Centro Hospitalar de Sao Joao E.P.E.
      • Córdoba, Spanien, 14004
        • Rekruttering
        • Hosp Reina Sofia
      • Sabadell, Spanien, 8208
        • Rekruttering
        • Corporacio Sanitari Parc Tauli
      • Valencia, Spanien, 46026
        • Rekruttering
        • Hosp. Univ. I Politecni La Fe
      • Busan, Sydkorea, 48108
        • Rekruttering
        • Inje University Haeundae Paik Hospital
      • Daegu, Sydkorea, 41404
        • Rekruttering
        • Kyungpook National University Chilgok Hospital
      • Seoul, Sydkorea, 03080
        • Rekruttering
        • Seoul National University Hospital
      • Seoul, Sydkorea, 06351
        • Rekruttering
        • Samsung Medical Center
      • Seoul, Sydkorea, 120-752
        • Rekruttering
        • Severance Hospital Yonsei University Health System
      • Vienna, Østrig, 1090
        • Rekruttering
        • AKH - Medizinische Universitat Wien

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

2 år til 17 år (Barn)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Participants must have a diagnosis of Crohn's Disease (CD) or fistulizing CD, with active colitis, ileitis, or ileocolitis, confirmed at any time in the past by clinical, endoscopic, and histologic criteria.
  • Participants must have moderately to severely active CD (as defined by a baseline Pediatric Crohn's Disease Activity Index [PCDAI] score greater than or equal to [>=] 30)
  • Participants must have endoscopy with evidence of active CD defined as Simple Endoscopic Score for Crohn's Disease (SES-CD) score greater than or equal to (>=) 6 (or >=4 for participants with isolated ileal disease) within 1 month of receiving study intervention at Week 0
  • Participants must have a history of inadequate response, loss of response, or intolerance to immunomodulators (6-MP, AZA, or MTX), oral or IV corticosteroids, or biologic therapy/JAK inhibitor therapy; OR have a history of corticosteroid dependence; OR have a history of inadequate response to exclusive enteral nutrition (EEN)

Exclusion Criteria:

  • Participants has complications of CD such as symptomatic strictures or stenosis, short gut syndrome, or any other manifestation that might be anticipated to require surgery.
  • Participants must not have an abscess
  • Participants must not have any kind of bowel resection within 26 weeks or any other intra-abdominal surgery within 12 weeks of baseline

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Tredobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Open-label induction phase: Guselkumab Intravenously (IV)

Participants will receive guselkumab dose IV based on their body weight during the 12-week open-label induction phase.

Guselkumab will be administered subcutaneously.

Andre navne:
  • CNTO1959
  • TREMFYA

Guselkumab will be administered intravenously.

Andre navne:
  • CNTO1959
  • TREMFYA
Eksperimentel: Open-label induction phase: Guselkumab Subcutaneously (SC)

Participants will receive guselkumab dose SC based on their body weight during the 12-week open-label induction phase.

Guselkumab will be administered subcutaneously.

Andre navne:
  • CNTO1959
  • TREMFYA

Guselkumab will be administered intravenously.

Andre navne:
  • CNTO1959
  • TREMFYA
Eksperimentel: Double-blind maintenance phase: Guselkumab SC Dose Regimen 1

At the end of the induction phase, Week 12 responders will be randomized into the double-blind maintenance phase to receive guselkumab dose regimen 1 SC based on their body weight up to Week 48.

Guselkumab will be administered subcutaneously.

Andre navne:
  • CNTO1959
  • TREMFYA

Guselkumab will be administered intravenously.

Andre navne:
  • CNTO1959
  • TREMFYA
Eksperimentel: Double-blind Maintenance Phase: Guselkumab SC Dose Regimen 2

At the end of the induction phase, Week 12 responders will be randomized into the double-blind maintenance phase to receive guselkumab dose regimen 2 SC based on their body weight up to Week 48.

Guselkumab will be administered subcutaneously.

Andre navne:
  • CNTO1959
  • TREMFYA

Guselkumab will be administered intravenously.

Andre navne:
  • CNTO1959
  • TREMFYA
Eksperimentel: Open-label maintenance phase: Guselkumab SC

Week 12 non-responders will not be randomized and will enter an open-label maintenance phase to receive guselkumab SC dosing regimen based on their body weight up to Week 48.

Guselkumab will be administered subcutaneously.

Andre navne:
  • CNTO1959
  • TREMFYA

Guselkumab will be administered intravenously.

Andre navne:
  • CNTO1959
  • TREMFYA

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percentage of Participants with Clinical Remission at Week 52
Tidsramme: Week 52

Percentage of participants with clinical remission at Week 52 will be assessed. Clinical remission is defined as pediatric Crohn's Disease activity index (PCDAI) less than or equal to (<=) 10.

Week 52
Percentage of Participants Who Achieve Endoscopic Response at Week 52
Tidsramme: Week 52

Percentage of participants who achieve endoscopic response at Week 52 will be assessed. Endoscopic response is defined as greater than or equal to (>=) 50 percent (%) reduction (global) and greater than (>) 50% reduction (U.S specific) from simplified endoscopic score-Crohn's Disease (SES-CD) score at baseline.

Week 52

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percentage of Participants with Clinical Response at Week 12
Tidsramme: Week 12

Percentage of participants with clinical response at Week 12 will be assessed. Clinical responder is defined as a decrease from baseline in the PCDAI score of >=12.5 points with a total PCDAI score <30.

Week 12
Percentage of Participants with Clinical Response at Week 52
Tidsramme: Week 52

Percentage of participants with clinical response at Week 52 will be assessed. Clinical responder is defined as a decrease from baseline in the PCDAI score of >=12.5 points with a total PCDAI score <30.

Week 52
Percentage of Participants with Clinical Remission at Week 12
Tidsramme: Week 12

Percentage of participants with clinical remission at Week 12 will be assessed. Clinical remission is defined as PCDAI score <=10.

Week 12
Percentage of Participants with Endoscopic Remission at Week 52
Tidsramme: Week 52

Percentage of participants with endoscopic remission at Week 52 will be assessed. Endoscopic remission is defined as SES-CD total score <=4 and at least a 2-point reduction from baseline and no subscore >1.

Week 52
Percentage of Participants with Corticosteroid-free Remission at Week 52
Tidsramme: Week 52

Percentage of participants with corticosteroid-free remission at Week 52 will be assessed. Corticosteroid-free remission is defined as PCDAI score <=10 at Week 52 and not receiving corticosteroids for at least 90 days before Week 52.

Week 52
Percentage of Participants with Sustained Clinical Remission at Weeks 12, 24, and 52
Tidsramme: Weeks 12, 24, and 52

Percentage of participants with sustained clinical remission at Weeks 12, 24, and 52 will be assessed. Sustained clinical remission is defined as PCDAI <=10 at Weeks 12, 24, and 52.

Weeks 12, 24, and 52
Percentage of Participants with Clinical remission by Patient-Reported Outcome (PRO-2)
Tidsramme: Week 12 and/or Week 52

Percentage of participants with clinical remission by PRO-2 will be assessed. Clinical remission by PRO-2 is defined as stool frequency (SF) <=3 and abdominal pain (AP) <=1 and no worsening of SF and AP from baseline.

Week 12 and/or Week 52
Serum Concentration of Guselkumab During Induction Phase
Tidsramme: From Week 0 to Week 12

Serum concentrations of guselkumab will be assessed. Serum samples will be analyzed to determine concentrations of guselkumab using a validated, specific, and sensitive immunoassay method.

From Week 0 to Week 12
Trough Plasma Concentration (Ctrough) of Guselkumab During Maintenance Phase
Tidsramme: At Weeks 16, 24, 36, 48 and 52

Ctrough is defined as the serum concentration of guselkumab immediately prior (pre-dose) to the next drug administration.

At Weeks 16, 24, 36, 48 and 52
Change from Baseline in Body Weight at Weeks 12, 24, and 52
Tidsramme: Baseline, Weeks 12, 24, and 52

Change from baseline in body weight at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Change from Baseline in Body Weight Percentiles at Weeks 12, 24, and 52
Tidsramme: Baseline, Weeks 12, 24, and 52

Change from baseline in body weight percentiles at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Change from Baseline in Body Weight z-scores at Weeks 12, 24, and 52
Tidsramme: Baseline, Weeks 12, 24, and 52

Change from baseline in body weight z-scores at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Change from Baseline in Height at Weeks 12, 24, and 52
Tidsramme: Baseline, Weeks 12, 24, and 52

Change from baseline in height at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Change from Baseline in Height Percentiles at Weeks 12, 24, and 52
Tidsramme: Baseline, Weeks 12, 24, and 52

Change from baseline in height percentiles at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Change from Baseline in Height z-scores at Weeks 12, 24, and 52
Tidsramme: Baseline, Weeks 12, 24, and 52

Change from baseline in height z-scores at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Change from Baseline in Height Velocity at Weeks 12, 24, and 52
Tidsramme: Baseline, Weeks 12, 24, and 52

Change from baseline in height velocity at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Percentage of Participants with Clinical Remission
Tidsramme: Week 52

Percentage of participants with clinical remission who were assigned to guselkumab dose regimen 1 and did not receive rescue therapy at Week 52 will be assessed. Clinical remission is defined as PCDAI score <=10.

Week 52
Percentage of Participants Who Achieve Endoscopic Response
Tidsramme: Week 52

Percentage of participants who achieve endoscopic response who were assigned to q4w maintenance therapy and did not receive rescue therapy at Week 52 will be assessed. Endoscopic response is defined as >=50% reduction (global) and >50% reduction (U.S specific) from SES-CD score at baseline.

Week 52
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsramme: Up to Week 64

An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product that does not necessarily have a causal relationship with the intervention. An SAE is is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product and is medically important.

Up to Week 64

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Studieleder: Clinical Trial, Janssen Research & Development, LLC

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

13. marts 2024

Primær færdiggørelse (Anslået)

27. oktober 2027

Studieafslutning (Anslået)

14. august 2028

Datoer for studieregistrering

Først indsendt

20. juni 2023

Først indsendt, der opfyldte QC-kriterier

20. juni 2023

Først opslået (Faktiske)

28. juni 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

3. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • CR109212
  • 2021-006282-37 (EudraCT nummer)
  • CNTO1959PBCRD3007 (Anden identifikator: Janssen Research & Development, LLC)
  • 2023-504735-41-00 (Registry Identifier: EUCT number)
  • 2023 (U.S. NIH-bevilling/kontrakt)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner